前列腺癌中的心血管风险——行动呼吁？ - Suppr

Suppr

超能文献

Cardiovascular Risk in Prostate Cancer-A Call to Action?

作者信息

Atkins Katelyn M, Nikolova Andriana P

机构信息

Department of Radiation Oncology, Cedars Sinai Medical Center, Los Angeles, California.

Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California.

出版信息

JAMA Oncol. 2024 Jul 1;10(7):885-886. doi: 10.1001/jamaoncol.2024.0860.

DOI:10.1001/jamaoncol.2024.0860

PMID:38842826

Abstract

摘要

相似文献

Cardiovascular Risk in Prostate Cancer-A Call to Action?

JAMA Oncol. 2024 Jul 1;10(7):885-886. doi: 10.1001/jamaoncol.2024.0860.

Cardiovascular Risk in Prostate Cancer.

Cardiol Clin. 2025 Feb;43(1):83-91. doi: 10.1016/j.ccl.2024.09.003. Epub 2024 Oct 5.

Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved.

Heart. 2012 Mar;98(5):345-8. doi: 10.1136/heartjnl-2011-300893. Epub 2011 Dec 7.

Androgen deprivation therapy for prostate cancer.

Lancet Oncol. 2017 Oct;18(10):e567. doi: 10.1016/S1470-2045(17)30670-8. Epub 2017 Sep 1.

Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial.

Prostate Cancer Prostatic Dis. 2022 Apr;25(4):657-658. doi: 10.1038/s41391-021-00483-5. Epub 2022 Jan 4.

Cardiovascular risk in ADT recipients: does the type of ADT matter?

Prostate Cancer Prostatic Dis. 2024 Sep;27(3):435-437. doi: 10.1038/s41391-024-00832-0. Epub 2024 Apr 25.

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.

J Natl Compr Canc Netw. 2023 Feb;21(2):163-171. doi: 10.6004/jnccn.2022.7083.

Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial.

J Clin Oncol. 2006 Sep 1;24(25):4184-9. doi: 10.1200/JCO.2005.05.4288.

A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.

Cancer. 2024 Jun 1;130(11):1916-1929. doi: 10.1002/cncr.35285. Epub 2024 Mar 26.

Letter: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone‒Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

J Urol. 2024 Mar;211(3):481. doi: 10.1097/JU.0000000000003830. Epub 2023 Dec 22.

引用本文的文献

Cancer treatment and survivorship statistics, 2025.

CA Cancer J Clin. 2025 Jul-Aug;75(4):308-340. doi: 10.3322/caac.70011. Epub 2025 May 30.

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.

Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Cardiovascular Risk in Prostate Cancer-A Call to Action?

JAMA Oncol. 2024 Jul 1;10(7):885-886. doi: 10.1001/jamaoncol.2024.0860.

Cardiovascular Risk in Prostate Cancer.

Cardiol Clin. 2025 Feb;43(1):83-91. doi: 10.1016/j.ccl.2024.09.003. Epub 2024 Oct 5.

Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved.

Heart. 2012 Mar;98(5):345-8. doi: 10.1136/heartjnl-2011-300893. Epub 2011 Dec 7.

Androgen deprivation therapy for prostate cancer.

Lancet Oncol. 2017 Oct;18(10):e567. doi: 10.1016/S1470-2045(17)30670-8. Epub 2017 Sep 1.

Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial.

Prostate Cancer Prostatic Dis. 2022 Apr;25(4):657-658. doi: 10.1038/s41391-021-00483-5. Epub 2022 Jan 4.

Cardiovascular risk in ADT recipients: does the type of ADT matter?

Prostate Cancer Prostatic Dis. 2024 Sep;27(3):435-437. doi: 10.1038/s41391-024-00832-0. Epub 2024 Apr 25.

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.

J Natl Compr Canc Netw. 2023 Feb;21(2):163-171. doi: 10.6004/jnccn.2022.7083.

Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial.

J Clin Oncol. 2006 Sep 1;24(25):4184-9. doi: 10.1200/JCO.2005.05.4288.

A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.

Cancer. 2024 Jun 1;130(11):1916-1929. doi: 10.1002/cncr.35285. Epub 2024 Mar 26.

Letter: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone‒Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

J Urol. 2024 Mar;211(3):481. doi: 10.1097/JU.0000000000003830. Epub 2023 Dec 22.

引用本文的文献

Cancer treatment and survivorship statistics, 2025.

CA Cancer J Clin. 2025 Jul-Aug;75(4):308-340. doi: 10.3322/caac.70011. Epub 2025 May 30.

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.

Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727.

Cardiovascular Risk in Prostate Cancer-A Call to Action?

作者信息

Atkins Katelyn M, Nikolova Andriana P

机构信息

Department of Radiation Oncology, Cedars Sinai Medical Center, Los Angeles, California.

Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California.

出版信息

JAMA Oncol. 2024 Jul 1;10(7):885-886. doi: 10.1001/jamaoncol.2024.0860.

DOI:10.1001/jamaoncol.2024.0860

PMID:38842826

Abstract

摘要